The Efficacy of Everolimus with Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient

Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Sep 2, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how effective a medication called everolimus, combined with a lower dose of another drug called tacrolimus, is in treating BK virus infections in kidney transplant recipients. BK virus can lead to serious kidney problems in patients who have received a transplant, and the usual treatment involves reducing the medications that help prevent the body from rejecting the new kidney. However, this trial is exploring whether adding everolimus can help patients who continue to have high levels of the virus after reducing their immunosuppressive drugs.

To be eligible for the trial, participants must be at least 18 years old and have had a kidney transplant at King Chulalongkorn Memorial Hospital. They should have persistent high levels of the BK virus in their blood, specifically more than 1,000 copies/mL on multiple tests. However, those with extremely high virus levels or a history of specific treatments for BK virus will not be able to participate. If you join the trial, you will receive careful monitoring and support throughout the study. This research could help find better ways to manage BK virus infections, ultimately improving the health of kidney transplant recipients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Kidney transplant recipients at King Chulalongkorn Memorial Hospital
• • age \>= 18 years
• • persistent BK viremia \>1000 copies/mL at least 2 times in 3 weeks or single time \> 10000 copies/mL
• Exclusion Criteria:
• • BK VL \>10\^5 log
• • Previous BKVAN treatment
• • Drug hypersensitivity to mTORi or leflunomide